117 related articles for article (PubMed ID: 10586356)
1. Idarubicin including regimens in acute myelogenous leukemia in elderly patients.
Leone G; Sica S; Pagano L
Crit Rev Oncol Hematol; 1999 Sep; 32(1):59-68. PubMed ID: 10586356
[No Abstract] [Full Text] [Related]
2. Escalated anthracycline dose in adult AML.
Balakrishnan VS
Lancet Oncol; 2017 May; 18(5):e253. PubMed ID: 28416149
[No Abstract] [Full Text] [Related]
3. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
4. The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Kobayashi T; Ichikawa M; Nannya Y; Kurokawa M
Jpn J Clin Oncol; 2013 Oct; 43(10):1047-51. PubMed ID: 23956441
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
6. 3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Creutzig U; Körholz D; Niemeyer CM; Kabisch K; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Leukemia; 2000 Feb; 14(2):340-2. PubMed ID: 10673757
[No Abstract] [Full Text] [Related]
7. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
8. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
9. 4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Fülle HH; Hellriegel KP
Haematol Blood Transfus; 1987; 30():343-5. PubMed ID: 3476366
[No Abstract] [Full Text] [Related]
10. Medical ethics collides with public policy: LVAD for a patient with leukemia.
McCarthy PM; Lamm RD; Sade RM
Ann Thorac Surg; 2005 Sep; 80(3):793-8. PubMed ID: 16122431
[No Abstract] [Full Text] [Related]
11. Idarubicin in refractory acute leukemia.
Fülle HH; Hellriegel KP
Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
[TBL] [Abstract][Full Text] [Related]
12. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
13. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
14. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
[No Abstract] [Full Text] [Related]
15. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
17. Lomustine in older patients with acute myeloid leukaemia.
Gourd E
Lancet Oncol; 2018 Nov; 19(11):e584. PubMed ID: 30293791
[No Abstract] [Full Text] [Related]
18. Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin.
Peña M; Serra J; Ribera JM
Med Clin (Barc); 2018 Dec; 151(12):506-507. PubMed ID: 29731139
[No Abstract] [Full Text] [Related]
19. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
[TBL] [Abstract][Full Text] [Related]
20. Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
Wood RA
Mayo Clin Proc; 2002 Oct; 77(10):1133. PubMed ID: 12374257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
